Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the transaction, the insider now directly owns 116,704 shares in the company, valued at approximately $1,839,255.04. This trade represents a 32.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Mineralys Therapeutics Stock Performance
Shares of NASDAQ MLYS opened at $13.53 on Friday. The stock has a market cap of $849.48 million, a price-to-earnings ratio of -3.72 and a beta of -0.39. The business has a 50 day simple moving average of $11.85 and a 200 day simple moving average of $12.27. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. On average, analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Analyst Ratings Changes
Several research firms recently commented on MLYS. The Goldman Sachs Group decreased their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, February 13th. HC Wainwright boosted their price target on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th.
View Our Latest Analysis on MLYS
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in MLYS. BNP Paribas Financial Markets acquired a new stake in Mineralys Therapeutics in the 4th quarter worth approximately $48,000. ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Mineralys Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock worth $130,000 after buying an additional 989 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Mineralys Therapeutics in the 4th quarter valued at $145,000. Finally, PDT Partners LLC bought a new position in Mineralys Therapeutics in the 3rd quarter worth $148,000. Institutional investors and hedge funds own 84.46% of the company's stock.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
